11 December 2020

Boehringer Ingelheim and the shareholders of NBE-Therapeutics have signed a share purchase agreement with a total transaction value of EUR 1.18bn which also includes contingent clinical and regulatory milestones. NBE-Therapeutics in Basel is a private, clinical-stage biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. VISCHER AG advised NBE-Therapeutics and its shareholders in this transaction. The team was led by Matthias Staehelin with Vincent Reardon, Pauline Pfirter, Céderic Saladin (all Corporate) and Nadia Tarolli (Tax).

Categories: Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Private Equity & Venture Capital, Startup Desk

You are currently offline. Some pages or content may fail to load.